Business Context and Reporting Period
This Form 8-K is filed by Neuralstem, Inc. (not Palisade Bio, Inc.) on April 13, 2011, reporting an event that occurred on April 12, 2011. The filing serves as a Regulation FD disclosure regarding interim safety data from a Phase I clinical trial.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial progress and does not contain financial statements.
Material Changes
The material event reported is the presentation of interim safety data by Dr. Eva Feldman, Principal Investigator and unpaid consultant, concerning the first nine patients in the Phase I safety trial of the Company's human spinal cord stem cells (HSSC) for the treatment of amyotrophic lateral sclerosis (ALS).
Guidance, Outlook, and Risks
The filing includes a press release (Exhibit 99.01) detailing the safety data presentation. The document explicitly states that the information is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings unless expressly stated. No specific financial guidance or forward-looking projections are included in this text.
Investor Verification Checklist
- Verify the full content of the attached press release (Exhibit 99.01) for specific safety outcomes of the nine patients.
- Confirm the current status of the Phase I trial for HSSC in ALS beyond the interim data point.
- Review recent 10-Q or 10-K filings for the most up-to-date financial position, as this 8-K contains no financial data.
- Monitor for any subsequent filings regarding the expansion of the trial or regulatory feedback based on this interim data.